HLTHCue Health Inc.

Nasdaq cuehealth.com


$ 0.12 $ 0.01 (7.94 %)    

Tuesday, 14-May-2024 15:57:43 EDT
QQQ $ 445.88 $ 2.85 (0.64 %)
DIA $ 395.58 $ 1.12 (0.28 %)
SPY $ 523.16 $ 2.39 (0.46 %)
TLT $ 90.86 $ 0.51 (0.56 %)
GLD $ 218.12 $ 1.83 (0.85 %)
$ 0.1319
$ 0.11
$ 0.00 x 0
$ 0.00 x 0
$ 0.11 - $ 0.12
$ 0.09 - $ 0.89
1,391,832
na
20.16M
$ 1.54
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-13-2024 12-31-2023 10-K
2 11-08-2023 09-30-2023 10-Q
3 08-09-2023 06-30-2023 10-Q
4 05-10-2023 03-31-2023 10-Q
5 03-16-2023 12-31-2022 10-K
6 11-09-2022 09-30-2022 10-Q
7 08-10-2022 06-30-2022 10-Q
8 05-11-2022 03-31-2022 10-Q
9 03-29-2022 12-31-2021 10-K
10 11-10-2021 09-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 reported-earlier-fda-issues-warning-to-cue-health-over-emergency-use-authorized-eua-covid-19-test

The Company is currently evaluating the letter and determining its response, with more information to follow in the next few days.

 fda-says-inspection-revealed-cue-health-is-not-complying-with-some-conditions-of-authorization-in-letters-of-authorization-for-eua200248--eua210180

- Reuters

 on-may-9-cue-health-got-warning-letter-from-fda-says-during-inspection-investigator-determined-cue-health-markets-distributes-cue-health-covid-19-test--cue-health-covid-19-test-for-home--otc-use

- Reuters

 cue-health-disclosed-it-has-been-undertaking-comprehensive-review-of-strategic-alternative-strategic-review-process-to-evaluate-options-including-potential-sale

-SEC Filing

 cue-health-reveals-strategic-actions-names-clint-sever-as-ceo-seeks-to-refine-and-strengthen-its-overarching-strategy-and-cost-structure

Clint Sever, co-founder and current Chief Product Officer, has been appointed CEO, effective immediately. Sever succeeds Ayub K...

 btig-downgrades-cue-health-to-neutral

BTIG analyst Mark Massaro downgrades Cue Health (NASDAQ:HLTH) from Buy to Neutral.

 cue-health-q4-earnings-insights
Cue Health: Q4 Earnings Insights
03/13/2024 20:10:24

 cue-health-q4-2023-adj-eps-032-beats-044-estimate-sales-18798m-beat-17681m-estimate

Cue Health (NASDAQ:HLTH) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.44) by...

 earnings-scheduled-for-march-13-2024

Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share...

 cue-healths-earnings-outlook
Cue Health's Earnings Outlook
03/12/2024 16:01:56

 why-zscaler-shares-are-trading-lower-by-10-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of Zscaler, Inc. (NASDAQ: ZS) shares fell sharply during Friday’s session following second-quarter results.

 why-netapp-shares-are-trading-higher-by-around-17-here-are-20-stocks-moving-premarket

Shares of NetApp, Inc. (NASDAQ: NTAP) shares rose sharply in today’s pre-market trading after the company reported better-than...

 cue-health-has-received-a-decision-to-grant-european-patent-number-ep3191849-titled-systems-and-methods-for-detection-and-quantification-of-analytes

https://register.epo.org/application?number=EP15771337

 hlth-cue-health-says-estimates-will-record-aggregate-restructuring-charge-related-to-one-time-termination-benefits-in-range-of-about-32m-to-40m

-SEC Filing

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION